Multidrug-resistant breast cancer: current perspectives

Heather L Martin,1 Laura Smith,2 Darren C Tomlinson11BioScreening Technology Group, Leeds Institutes of Molecular Medicine, University of Leeds, Leeds, UK; 2Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UKAbstract: Breast cancer is the most common cancer in women worldwide, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martin HL, Smith L, Tomlinson DC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cf782eab03c54343a1797a388524479b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf782eab03c54343a1797a388524479b
record_format	dspace
spelling	oai:doaj.org-article:cf782eab03c54343a1797a388524479b2021-12-02T01:31:24ZMultidrug-resistant breast cancer: current perspectives1179-1314https://doaj.org/article/cf782eab03c54343a1797a388524479b2014-01-01T00:00:00Zhttp://www.dovepress.com/multidrug-resistant-breast-cancer-current-perspectives-a15476https://doaj.org/toc/1179-1314 Heather L Martin,1 Laura Smith,2 Darren C Tomlinson11BioScreening Technology Group, Leeds Institutes of Molecular Medicine, University of Leeds, Leeds, UK; 2Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UKAbstract: Breast cancer is the most common cancer in women worldwide, and resistance to the current therapeutics, often concurrently, is an increasing clinical challenge. By understanding the molecular mechanisms behind multidrug-resistant breast cancer, new treatments may be developed. Here we review the recent advances in this understanding, emphasizing the common mechanisms underlying resistance to both targeted therapies, notably tamoxifen and trastuzumab, and traditional chemotherapies. We focus primarily on three molecular mechanisms, the phosphatidylinositide 3-kinase/Akt pathway, the role of microRNAs in gene silencing, and epigenetic alterations affecting gene expression, and discuss how these mechanisms can interact in multidrug resistance. The development of therapeutics targeting these mechanisms is also addressed.Keywords: PI3K/Akt, epigenetics, miRNA, ER, HER2, triple negativeMartin HLSmith LTomlinson DCDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 1-13 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Martin HL Smith L Tomlinson DC Multidrug-resistant breast cancer: current perspectives
description	Heather L Martin,1 Laura Smith,2 Darren C Tomlinson11BioScreening Technology Group, Leeds Institutes of Molecular Medicine, University of Leeds, Leeds, UK; 2Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UKAbstract: Breast cancer is the most common cancer in women worldwide, and resistance to the current therapeutics, often concurrently, is an increasing clinical challenge. By understanding the molecular mechanisms behind multidrug-resistant breast cancer, new treatments may be developed. Here we review the recent advances in this understanding, emphasizing the common mechanisms underlying resistance to both targeted therapies, notably tamoxifen and trastuzumab, and traditional chemotherapies. We focus primarily on three molecular mechanisms, the phosphatidylinositide 3-kinase/Akt pathway, the role of microRNAs in gene silencing, and epigenetic alterations affecting gene expression, and discuss how these mechanisms can interact in multidrug resistance. The development of therapeutics targeting these mechanisms is also addressed.Keywords: PI3K/Akt, epigenetics, miRNA, ER, HER2, triple negative
format	article
author	Martin HL Smith L Tomlinson DC
author_facet	Martin HL Smith L Tomlinson DC
author_sort	Martin HL
title	Multidrug-resistant breast cancer: current perspectives
title_short	Multidrug-resistant breast cancer: current perspectives
title_full	Multidrug-resistant breast cancer: current perspectives
title_fullStr	Multidrug-resistant breast cancer: current perspectives
title_full_unstemmed	Multidrug-resistant breast cancer: current perspectives
title_sort	multidrug-resistant breast cancer: current perspectives
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/cf782eab03c54343a1797a388524479b
work_keys_str_mv	AT martinhl multidrugresistantbreastcancercurrentperspectives AT smithl multidrugresistantbreastcancercurrentperspectives AT tomlinsondc multidrugresistantbreastcancercurrentperspectives
_version_	1718403042122924032

Multidrug-resistant breast cancer: current perspectives

Ejemplares similares